- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07561346
Clinico-pathological and Genomic Features of HER2-low Early Breast Cancer
Clinico-pathological and Genomic Features of HER2-low Early Breast Cancer (eBC). Results of Retrospective Analysis of Seven Adjuvant Trials by the Hellenic Cooperative Oncology Group (HeCOG)
Although breast cancer remains one of the most common and fatal cancer types among women worldwide, earlier diagnosis and improved therapeutic approaches have led to decreased mortality over last years. Indeed, the use of HER2-targeted drugs has improved clinical outcomes for patients with HER2 positive breast cancer, while, on the other hand, until recently, little progress has been made for HER2-negative (IHC score 0 and 1+) patients.
However, it seems that among these HER2-negative breast cancers, substantial heterogeneity exists regarding the expression of hormone receptors (HR) and HER2.
Biomarkers are critical for translating the biological heterogeneity of breast cancer into prognostically and therapeutically useful information. In recent years gene expression profiling and genomic analysis have shown utility in specific clinical scenarios, but immunohistochemistry (IHC) remains the cornerstone of biomarker testing in both early and advanced/metastatic disease.
In breast cancer, achieving efficacy with endocrine therapy or with HER2-blockade requires identifying patients whose tumors show significant survival dependency on the therapeutic target. This is achieved by using appropriate biomarkers cut-offs ensuring a favorable benefit-to-toxicity ratio for specific patients.
This paradigm has recently been challenged by a new class of HER2 drugs that use target expression not as a direct molecular lever but as a vehicle to deliver potent agents to cancer cells, breaking the straightforward link between the molecular target and the corresponding therapy. These drugs exhibit impressive activity at marker expression levels much lower than those required to effectively block HER2 signaling, shifting the diagnostic focus to the lower end of the staining spectrum, specifically distinguishing between HER2-zero and HER2-low expression.
Given the lack of a definitive molecular hallmark for cancers characterized by low HER2 expression, ongoing efforts aim to understand the biology of this heterogeneous group of tumors. This understanding is crucial to triage treatment, investigate resistance mechanisms, and inform potential combination strategies.
To enrich the available data, we perform a retrospective analysis of HER2-low patients in a large cohort of early breast cancer patients from Greece enrolled in 7 randomized and observational clinical studies.
Given the importance of the hormone receptors and the known differential distribution of ER/PgR status between HER2-zero, HER2-low and HER2-positive breast tumors, after analyzing the entire population cohort, ER/PgR status will be treated as a confounding variable in the analysis and the HER2 categories will be compared separately within ER/PR-positive and ER/PR-negative disease.
The study aims to investigate how HER2-zero, HER2-low and HER2-positive tumors are distributed across ER expression categories. Additionally, we will evaluate whether PgR positivity varies across ER expression categories, and if PgR identify heterogeneity within ER-low tumors.
As TP53 mutation is strongly linked to basal-like, high-grade, hormone receptor-negative and HER2-positive biology, we will examine if TP53 mutation frequency differs across ER categories and classic subtypes and if PIK3CA mutation frequency differs across ER categories and PgR-defined groups, as PIK3CA mutations are generally enriched in luminal breast cancer.
TIL biology is also strongly subtype-dependent. TNBC and HER2-positive disease are generally more immune-enriched than luminal disease, so we will examine if stromal TIL levels are associated with ER category, HER2 category and classic subtype in our study.
Summarizing, our aim is to evaluate if HER2-low status retains independent associations with clinicopathologic, immune or genomic features after adjustment for ER category and classic subtype, whether ER/HER2 matrix groups are associated with disease outcome, and associations remain after adjustment for standard prognostic factors and treatment.
Studie Overzicht
Toestand
Gedetailleerde beschrijving
From 1996 until 2020, 5,320 eligible patients with operable breast cancer were treated, within the context of 3 randomized and 4 observational clinical studies with dds-CT including taxanes and anthracyclines. Adjuvant hormonal and radiation treatment were administered, as indicated.
IHC and FiSH data from patients enrolled in the above randomized phase III trials conducted by the Hellenic Cooperative Oncology Group (HeCOG) will be retrospectively reviewed.
All patients have signed a study-specific written informed consent before randomization, consenting for the trial and permitting the use of their biological material for future research purposes. All studies were conducted in accordance with the Declaration of Helsinki.
Tumor material is examined mainly on tissue microarrays (TMA). Although, there is a HER2 assessment from local pathology laboratories, all tumors are re-evaluated centrally for ER, PgR and HER2 in the laboratory of Molecular Oncology according to ASCO/CAP guidelines. Tumors are subtyped with immunohistochemistry (IHC4) for ER, PgR, HER2 and Ki67. FISH is performed for the assessment of HER2 gene status. IHC for EGFR and CK5 is used for the classification of basal-like tumors; the expression of CD8 on TILs is also evaluated. Moreover, we investigate the mutational profile of Greek women with breast cancer, via the application of DNA Next Generation Sequencing (NGS) technologies, relative also to patient outcome.
Patient demographic, clinicopathological and treatment data are available in all cases.
Studietype
Inschrijving (Werkelijk)
Contacten en locaties
Studie Locaties
-
-
-
Athens, Griekenland, 11526
- Hellenic Cooperative Oncology Group (HeCOG)
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
patients with operable breast cancer treated with dds-CT including taxanes and anthracyclines. Adjuvant hormonal and radiation treatment were administered, as indicated
Beschrijving
Inclusion Criteria:
- Age 18 and above
- Histologically confirmed BC
- All treated with adjuvant dose-dense sequential chemotherapy (dds-CT)
- Tumor tissue specimen (FFPE) availability
Exclusion Criteria:
- not adequate, and unsuitable tissue for IHC, FISH, NGS analysis
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: COHORT
- Tijdsperspectieven: RETROSPECTIVE
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Overall Survival (OS)
Tijdsspanne: Time from study entry to death from any cause, assessed up to 120 months]
|
To investigate the long-term prognostic significance of HER2 positive, HER2 low and HER2 zero in terms of OS |
Time from study entry to death from any cause, assessed up to 120 months]
|
|
Disease-Free Survival (DFS)
Tijdsspanne: Time from study entry to first recurrence (local, regional, distant) or death from any cause, whichever comes first, assessed up to 120 months]
|
To investigate the long-term prognostic significance of HER2 positive, HER2 low and HER2 zero in term of DFS |
Time from study entry to first recurrence (local, regional, distant) or death from any cause, whichever comes first, assessed up to 120 months]
|
Medewerkers en onderzoekers
Publicaties en nuttige links
Algemene publicaties
- Schettini F, Chic N, Braso-Maristany F, Pare L, Pascual T, Conte B, Martinez-Saez O, Adamo B, Vidal M, Barnadas E, Fernandez-Martinez A, Gonzalez-Farre B, Sanfeliu E, Cejalvo JM, Perrone G, Sabarese G, Zalfa F, Peg V, Fasani R, Villagrasa P, Gavila J, Barrios CH, Lluch A, Martin M, Locci M, De Placido S, Prat A. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer. 2021 Jan 4;7(1):1. doi: 10.1038/s41523-020-00208-2.
- Curigliano G, Dent R, Earle H, Modi S, Tarantino P, Viale G, Tolaney SM. Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer. ESMO Open. 2024 Apr;9(4):102989. doi: 10.1016/j.esmoop.2024.102989. Epub 2024 Apr 12.
- Patel A, Unni N, Peng Y. The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer. Cancers (Basel). 2020 Jul 28;12(8):2081. doi: 10.3390/cancers12082081.
- Jokhadze N, Das A, Dizon DS. Global cancer statistics: A healthy population relies on population health. CA Cancer J Clin. 2024 May-Jun;74(3):224-226. doi: 10.3322/caac.21838. Epub 2024 Apr 4. No abstract available.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Andere studie-ID-nummers
- HE_10L/25
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .